Application of Conductive Hydrogel Combined with Electrical Stimulation in the Treatment of Diabetic Foot Ulcers Caused by Neuropathy

Abstract

The present invention discloses the application of a conductive hydrogel combined with electrical stimulation in the treatment of diabetic foot ulcers caused by neuropathy, belonging to the field of biomedicine. The conductive hydrogel is obtained by mixing chitosan, polyvinyl alcohol, MXene and gelatin. The chitosan is chitosan modified with catechol groups, the MXene is MXene modified with polyphenols and Mg ions, and the gelatin is gelatin modified with phenylboronic acid. The condition of the electrical stimulation is 100 mV cm-1. The diabetic foot ulcers include diabetic foot ulcers caused by neuropathy. Through experimental verification, the conductive hydrogel prepared by the present invention combined with electrical stimulation can promote cell migration, accelerate the wound healing of diabetic foot ulcers and achieve functional repair. The present invention provides a new idea for the clinical treatment of diabetic foot ulcers caused by neuropathy.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and particularly to the application of a conductive hydrogel combined with electrical stimulation in the treatment of diabetic foot ulcers caused by neuropathy. Background Art

[0002] Diabetic neuropathy is the most common complication, occurring in approximately 50% of diabetic patients. It is mainly manifested as impaired nerve regeneration ability and sensorimotor disorders. If not treated properly, it will ultimately lead to ulcers, infections, and gangrene in the lower extremities. On the other hand, approximately 34% of diabetic patients develop diabetic foot ulcers (DFUs), and patients with neuropathy are more prone to DFUs. After the wound appears, impaired blood supply and ROS accumulation will immediately trigger an inflammatory response, further aggravating vascular and nerve lesions. Diabetic foot ulcers caused by diabetic neuropathy are difficult to heal and carry the risk of amputation and death, which greatly reduces the overall health level and quality of life of patients. Although various methods for treating diabetic foot ulcers have emerged in recent years, their efficacy for diabetic foot ulcers caused by neuropathy is still limited. Therefore, there is an urgent need for an effective treatment strategy for DFUs caused by neuropathy. Summary of the Invention

[0003] The purpose of the present invention is to provide the application of a conductive hydrogel combined with electrical stimulation in the treatment of diabetic foot ulcers caused by neuropathy, so as to solve the problems existing in the above-mentioned prior art. The conductive hydrogel combined with electrical stimulation prepared by the present invention can promote cell migration, accelerate the wound healing of diabetic foot ulcers and achieve functional repair. The present invention provides a new idea for the clinical treatment of diabetic foot ulcers caused by neuropathy.

[0004] To achieve the above purpose, the present invention provides the following solution:

[0005] The present invention provides the application of a conductive hydrogel combined with electrical stimulation in the preparation of a drug for treating diabetic foot ulcers, wherein the conductive hydrogel is obtained by mixing chitosan, polyvinyl alcohol, MXene, and gelatin;

[0006] The chitosan is chitosan modified with catechol groups, the MXene is MXene modified with polyphenols and Mg ions, and the gelatin is gelatin modified with phenylboronic acid.

[0007] Optionally, the catechol group-modified chitosan is prepared by the following method: dissolving chitosan to obtain a chitosan solution, adding dihydrocaffeic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide, reacting in an argon atmosphere, and obtaining the catechol group-modified chitosan through dialysis, diafiltration, and freeze-drying; the mass ratio of chitosan, dihydrocaffeic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide, and N-hydroxysuccinimide is (50-80):(26-45.5):(24-30):(15-20);

[0008] The polyphenol and Mg ion-modified MXene is prepared by the following method: epigallocatechin gallate or gallic acid is added to the MXene dispersion, and then MgCl2·6H2O is added, followed by stirring reaction, washing and centrifuging with deionized water, and collecting the precipitate, which is the polyphenol and Mg ion-modified MXene; the mass ratio of epigallocatechin gallate or gallic acid, MXene, and MgCl2·6H2O is (1-5):1:(5-6);

[0009] The phenylboronic acid-modified gelatin is prepared by the following method: N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride are added to gelatin and stirred evenly, and then N-phenylbenzamide is added and stirred in a water bath, and the phenylboronic acid-modified gelatin is obtained through dialysis and freeze-drying; the mass ratio of gelatin, N-hydroxysuccinimide, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, and N-phenylbenzamide is (4-6):(7-10):(2-3):(3.5-5);

[0010] The conductive hydrogel is obtained by mixing and reacting catechol group-modified chitosan, polyvinyl alcohol, and water in a ratio of 0.1 g:1 g:10 mL to obtain solution A; mixing and reacting polyphenol and Mg ion-modified MXene with phenylboronic acid-modified gelatin in a mass ratio of (0.8-1.6):12.5 to obtain solution B; and mixing and reacting solution A and B in a volume ratio of 1:1.

[0011] Optionally, the condition of the electrical stimulation is 100 mV cm -1 .

[0012] Optionally, the diabetic foot ulcer includes a diabetic foot ulcer caused by neuropathy.

[0013] Optionally, the conductive hydrogel plays a role in treating diabetic foot ulcers by promoting cell migration.

[0014] The present invention also provides a hydrogel preparation for treating diabetic foot ulcers, comprising the conductive hydrogel;

[0015] The hydrogel preparation is combined with electrical stimulation for the treatment of diabetic foot ulcers.

[0016] Optionally, the conditions of the electrical stimulation are 100 mV cm -1 .

[0017] Optionally, the diabetic foot ulcer includes a diabetic foot ulcer caused by neuropathy.

[0018] Optionally, the conductive hydrogel plays a role in treating diabetic foot ulcers by promoting cell migration.

[0019] The present invention discloses the following technical effects:

[0020] The main raw materials of the conductive hydrogel synthesized by the present invention are widely sourced, have good biocompatibility and are non-toxic, which is conducive to the commercialization of the product; and the hydrogel gelation process is easy and the gelation speed is fast.

[0021] Verified by experiments, the conductive hydrogel prepared by the present invention combined with electrical stimulation can promote cell migration, accelerate the wound healing of diabetic foot ulcers and achieve functional repair. It can be seen that the conductive hydrogel prepared by the present invention combined with electrical stimulation can treat diabetic foot ulcers caused by neuropathy, and the present invention provides a new idea for the clinical treatment of diabetic foot ulcers caused by neuropathy. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for use in the embodiments. Obviously, the drawings in the following description are only some embodiments of the present invention, and those of ordinary skill in the art can also obtain other drawings based on these drawings without creative efforts.

[0023] Figure 1 It is a diagram of the gelation steps of the conductive hydrogel in Example 1;

[0024] Figure 2 It is a diagram of the cell migration experiment results within 24 hours in Example 1; the left figure is a picture of the cell migration experiment; the right figure is a statistical chart of the migration rate;

[0025] Figure 3 It is a diagram of the wound treatment effect in 16 days in Example 1; the left figure is a picture of the wound; the right figure is a statistical chart of the remaining wound area;

[0026] Figure 4 It is a Masson staining diagram of the wound surface in Example 1. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0027] The various exemplary embodiments of the present invention will be described in detail. This detailed description should not be construed as a limitation on the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0028] It should be understood that the terms used in the present invention are only for describing particular embodiments and are not intended to limit the present invention. Additionally, for the numerical ranges in the present invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any intermediate value within any stated value or stated range, as well as each smaller range between any other stated value or intermediate value within the stated range, is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0029] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention pertains. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the said documents. In case of conflict with any incorporated document, the content of this specification shall prevail.

[0030] Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific embodiments of the present invention specification, which are obvious to those skilled in the art. Other embodiments obtained from the specification of the present invention are obvious to those skilled in the art. The specification and examples of the present invention are merely exemplary.

[0031] Regarding the use of "comprising", "including", "having", "containing", etc. herein, they are all open-ended terms, meaning including but not limited to.

[0032] Example 1

[0033] 1. Preparation of conductive hydrogel

[0034] The preparation steps are as Figure 1 shown. The modified chitosan (CSDA) and polyvinyl alcohol (PVA) are mixed and reacted to obtain solution A, and the polyphenol and Mg ion-modified nanosheets (MXene@EGCG-Mg) and the modified gelatin (GPBA) are mixed and reacted to obtain solution B. Solution A and B are mixed and reacted in a certain proportion and then refrigerated at low temperature to obtain the conductive hydrogel.

[0035] 1.1 Preparation of modified MXene nanosheets

[0036] First, 1 g of LiF was added to 20 mL of 9 M hydrochloric acid solution and stirred thoroughly for reaction. Then, 1 g of Ti3AlC2 was slowly added and the mixture was stirred for reaction at 35 - 45 °C for 26 h. The precipitate was collected, resuspended in deionized water, centrifuged at 4500 rpm for 5 min, and washed multiple times until the pH value of the supernatant reached 6. Then, the precipitate was collected, 60 mL of deionized water was added, and it was ultrasonically dispersed in an Ar environment for 1 h. The supernatant was collected by centrifugation to obtain the MXene nanosheet dispersion. 10 mg of EGCG (epigallocatechin gallate) was dissolved in Tris with pH = 8.5, and then slowly added dropwise to the 10 mg / mL MXene nanosheet dispersion and stirred in the dark for 2 h. Then, 50 mg of MgCl2·6H2O was added to 2 mL of Tris solution and added dropwise into the above MXene nanosheet dispersion containing EGCG, and the mixture was continuously stirred for reaction for 1 h. Finally, it was centrifuged at 8000 rpm for 5 min, and the precipitate MXene@EGCG-Mg was collected after washing with deionized water.

[0037] 1.2 Preparation of catechol group-modified chitosan (CSDA)

[0038] 0.5 g of chitosan was dissolved in deionized water, and the pH was adjusted to 5.0 with HCl, and it was stirred in a 60 °C water bath for 20 min. Then, 260 mg of dihydrocaffeic acid was dissolved in 5.0 mL of deionized water, and after being stirred and dissolved thoroughly, it was added to the chitosan solution. 240 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and 150 mg of N-hydroxysuccinimide (NHS) were dissolved in an ethanol solution (a 1:1 mixture of 50.0 mL of ethanol and deionized water). Subsequently, it was added to the above chitosan solution containing HCA, and after introducing Ar, the reaction was carried out at room temperature for 12 h. Subsequently, the solution was dialyzed in acidified deionized water for 2 d, then dialyzed in deionized water for another half day, and finally freeze-dried in a freeze dryer to obtain a yellow solid (CSDA).

[0039] 1.3 Preparation of phenylboronic acid-modified gelatin (GPBA)

[0040] 4 g of gelatin was added to 400 mL of deionized water and stirred thoroughly at 70 °C. 7 g of N-hydroxysuccinimide (NHS) and 2 g of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) powder were added to the above solution and stirred evenly, and the pH was adjusted to 5 with 1 M hydrochloric acid solution. Then, 3.5 g of N-phenylbenzamide (PBA) powder was added, and the reaction was carried out by stirring in a 37 °C water bath for 48 h. Then, the obtained solution was dialyzed in deionized water for 3 days and then freeze-dried to obtain GPBA.

[0041] 1 g of PVA powder was added to 10 mL of deionized aqueous solution and dissolved at 95 °C. 0.1 g of CSDA was added to the dissolved PVA solution and stirred for 1 h to obtain solution A. Then, GPBA was prepared into a 12.5 wt% solution, 0.25 mL was taken, and 20 μL of 10 mg / mL MXene@EGCG-Mg was added to it to obtain solution B. Solution A and B were mixed and reacted according to a volume ratio of 1:1, and then placed in a refrigerator at -80 °C for 12 h and thawed at room temperature to obtain a conductive hydrogel (PCPM2).

[0042] 2. Cell migration experiment

[0043] PC12 cells were plated in 6-well plates at a density of 8×10 5 cells per well and cultured in a 5% CO2 incubator at 37 °C for 8 h. A direct cell scratch was made on each well of the plate with a 10 μL pipette tip, and the floating cells were thoroughly rinsed off. This moment was marked as the zero time point, and the samples were observed and photographed under a confocal microscope. Then, the cells were electrically stimulated with the hydrogel extract (applying an external electric field, the parameters of the electric stimulation were: 100 mV cm -1 ) for 30 min, and a control group without adding anything was set. After incubation for 12 and 24 h, the samples were observed and photographed under a confocal microscope.

[0044] The results are as Figure 2 shown, and the results show that compared with the control group, the conductive hydrogel combined with electrical stimulation can accelerate cell migration.

[0045] 3. Diabetic foot ulcer wound model experiment

[0046] A diabetic model was established using male Sprague-Dawley rats weighing about 350 g. After the rats were fasted for 12 h, streptozotocin (50 mg / kg) dissolved in 2% citric acid solution was injected intraperitoneally. After 7 d, blood glucose levels were randomly sampled from the rat tail vein for detection. A random blood glucose level exceeding 16.7 mmol / L indicated the successful establishment of a diabetic model. After 4 weeks, diabetic rats with neuropathy were screened by mechanical withdrawal threshold. All diabetic rats with neuropathy were anesthetized and a circular skin wound (diameter = 5 mm) was created on the dorsal foot with a skin puncher to obtain a diabetic foot ulcer wound model. A total of 12 diabetic rats with neuropathy were randomly assigned to two different groups: the control group and the PCPM2 group with electrical stimulation (applying an external electric field, the parameters of the electric stimulation were: 100 mV cm -1 ). The wound healing process was carefully observed and photographed at 0, 4, 8, 12, and 16 d.

[0047] On the 16th day after surgery, the animals were sacrificed, and the skin wounds and surrounding tissues of the feet were collected and fixed with 4.0% paraformaldehyde buffer solution. After 1 h, the samples were embedded in paraffin and prepared into 5-μm thick sections using a microtome for further Masson staining.

[0048] The wound healing situation was as Figure 3 shown. It can be seen that the conductive hydrogel combined with electrical stimulation can promote the repair of diabetic foot ulcers within 16 days, and the wound can be completely healed on the 16th day. The Masson staining images are shown in Figure 4 , and it can be found that the conductive hydrogel combined with electrical stimulation can increase the collagen density of the tissue and promote hair follicle formation.

[0049] Example 2

[0050] 1. Preparation of conductive hydrogel

[0051] 1.1 Preparation of modified MXene nanosheets

[0052] First, 2 g of LiF was added to 40 mL of 10 M hydrochloric acid solution and stirred thoroughly. Then, 2 g of Ti3AlC2 was slowly added and stirred at 35 °C for 28 h. The precipitate was collected, resuspended in deionized water, centrifuged at 4500 rpm for 8 min, and washed multiple times until the pH of the supernatant reached 6. Then, the precipitate was collected, added to 100 mL of deionized water, ultrasonically dispersed in an Ar environment for 1.5 h, and the supernatant was collected by centrifugation to obtain the MXene nanosheet dispersion. 50 mg of gallic acid (GA) was dissolved in Tris with pH = 8.5, and then slowly added dropwise to the 10 mg / mL MXene nanosheet dispersion and stirred in the dark for 2 h. Then, 60 mg of MgCl2·6H2O was added to 2 mL of Tris solution and added dropwise to the previous solution, and the stirring reaction was continued for 1 h. Finally, it was centrifuged at 10000 rpm for 5 min with deionized water, and the precipitate MXene@GA-Mg was collected by washing with deionized water.

[0053] 1.2 Preparation of catechol group-modified chitosan (CSDA)

[0054] 0.8 g of chitosan was dissolved in deionized water, and the pH was adjusted to 5.0 with HCl. The mixture was stirred in a water bath at 80 °C for 30 min. Then, 455 mg of dihydrocaffeic acid was dissolved in 8.0 mL of deionized water. After complete dissolution with sufficient stirring, it was added to the chitosan solution. 300 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) and 200 mg of N-hydroxysulfosuccinimide (NHS) were dissolved in an ethanol solution (a 1:1 mixture of 50.0 mL of ethanol and deionized water). Subsequently, it was added to the above chitosan solution containing HCA. After purging with Ar, the reaction was carried out at room temperature for 12 h. Subsequently, the solution was dialyzed in acidified deionized water for 3 days, then dialyzed in deionized water for another half day, and finally freeze-dried in a freeze dryer to obtain a yellow solid (CSDA).

[0055] 1.3 Preparation of phenylboronic acid-modified gelatin (GPBA)

[0056] 6 g of gelatin was added to 600 mL of deionized water and stirred thoroughly at 80 °C. 10 g of N-hydroxysulfosuccinimide (NHS) and 3 g of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) powder were added to the above solution and stirred evenly. Then, the pH was adjusted to 5 with 2 M hydrochloric acid solution. Then, 5 g of N-phenylbenzamide (PBA) powder was added and the reaction was stirred in a water bath at 45 °C for 48 h. The resulting solution was dialyzed in deionized water for 3 days and then freeze-dried.

[0057] 2 g of PVA powder was added to 20 mL of deionized water solution and dissolved at 100 °C. 0.2 g of CSDA was added to the dissolved PVA solution and stirred for another 2 h to obtain solution A. Then, GPBA was prepared into a 12.5 wt% solution. 0.25 mL of it was taken, and 40 μL of 10 mg / mL MXene@GA-Mg was added to obtain solution B. Solution A and B were mixed in a volume ratio of 1:1 and reacted, and then placed in a refrigerator at -80 °C for 48 h and thawed at room temperature to obtain a conductive hydrogel (PCPM2).

[0058] 2. Cell migration experiment

[0059] PC12 cells were plated in a 6-well plate at a density of 8×10 5 cells per well and cultured in a 5% CO2 incubator at 37 °C for 8 h. A direct cell scratch was made on each well of the plate with a 10 μL pipette tip, and the floating cells were thoroughly rinsed off. This moment was marked as the zero time point, and the samples were observed and photographed under a confocal microscope. Then, the cells were electrically stimulated with the hydrogel extract (applying an external electric field, and the parameters of the electric stimulation were: 100 mV cm -1) Set a control group without adding anything for 30 minutes. After incubation for 12 and 24 hours, observe and take pictures under a confocal microscope.

[0060] The results are Figure 2 the same, showing that the conductive hydrogel prepared in this example combined with electrical stimulation can accelerate cell migration.

[0061] 3. Diabetic foot ulcer wound model experiment

[0062] Establish a diabetic model using male Sprague-Dawley rats weighing approximately 350 g. After the rats are fasted for 12 hours, intraperitoneally inject streptozotocin (50 mg / kg) dissolved in 2% citric acid solution. After 7 d, randomly sample from the rat tail vein to detect blood glucose levels. A random blood glucose level exceeding 16.7 mmol / L indicates the successful establishment of a diabetic model. After 4 weeks, screen for diabetic rats with neuropathy through mechanical withdrawal thresholds. All diabetic rats with neuropathy are anesthetized and a circular skin wound (diameter = 5 mm) is created on the dorsal surface of the foot using a skin puncher to obtain a diabetic foot ulcer wound model. A total of 12 diabetic rats with neuropathy are randomly assigned to two different groups: a control group and a PCPM2 group with electrical stimulation (applying an external electric field, the parameters of the electrical stimulation are: 100 mV cm -1 ). Finally, carefully observe and take pictures of the wound healing process on days 0, 4, 8, 12, and 16.

[0063] On the 16th day after surgery, sacrifice the animals, collect the foot skin wound surface and surrounding tissues, and fix the tissues with 4.0% paraformaldehyde buffer solution. After 1 h, embed the samples in paraffin and use a microtome to prepare the samples into 5-μm thick sections for further Masson staining.

[0064] The wound healing conditions and staining results are Figure 3 、 Figure 4 the same. The conductive hydrogel combined with electrical stimulation can promote the repair of diabetic foot ulcers until complete healing within 16 days; the conductive hydrogel combined with electrical stimulation can cause a significant increase in collagen density in the tissue and the formation of hair follicles.

[0065] The embodiments described above are only descriptions of the preferred embodiments of the present invention and do not limit the scope of the present invention. Without departing from the design spirit of the present invention, various deformations and improvements made by those of ordinary skill in the art to the technical solutions of the present invention shall fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of a conductive hydrogel combined with electrical stimulation in the preparation of a drug for treating diabetic foot ulcers, characterized in that, The conductive hydrogel is obtained by mixing chitosan, polyvinyl alcohol, MXene and gelatin; The chitosan is chitosan modified with catechol groups, the MXene is MXene modified with polyphenols and Mg ions, and the gelatin is gelatin modified with phenylboronic acid; The chitosan modified with catechol groups is prepared by the following method: dissolving chitosan to obtain a chitosan solution, adding dihydrocaffeic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide, reacting in an argon environment, and obtaining the chitosan modified with catechol groups through dialysis, ultrafiltration and freeze-drying; the mass ratio of the chitosan, dihydrocaffeic acid, 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide is (50-80):(26-45.5):(24-30):(15-20); The MXene modified with polyphenols and Mg ions is prepared by the following method: adding epigallocatechin gallate or gallic acid to the MXene dispersion, and then adding MgCl2·6H2O, stirring and reacting, centrifuging and washing with deionized water, and collecting the precipitate, which is the MXene modified with polyphenols and Mg ions; the mass ratio of the epigallocatechin gallate or gallic acid, MXene and MgCl2·6H2O is (1-5):1:(5-6); The MXene dispersion is prepared by the following method: adding 1 g of LiF to 20 mL of a hydrochloric acid solution with a concentration of 9 M and stirring, slowly adding 1 g of Ti3AlC2 and stirring and reacting at 35-45 °C for 26 h; collecting the precipitate, resuspending it in deionized water, centrifuging at 4500 rpm for 5 min, and washing multiple times until the pH value of the supernatant reaches 6; collecting the precipitate, adding 60 mL of deionized water, ultrasonically dispersing it in an Ar environment for 1 h, and centrifuging to collect the supernatant, which is the MXene nanosheet dispersion; The gelatin modified with phenylboronic acid is prepared by the following method: adding N-hydroxysuccinimide and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride to gelatin and stirring evenly, then adding N-phenylbenzamide and stirring and reacting in a water bath, and obtaining the gelatin modified with phenylboronic acid through dialysis and freeze-drying; the mass ratio of the gelatin, N-hydroxysuccinimide, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-phenylbenzamide is (4-6):(7-10):(2-3):(3.5-5); The conductive hydrogel is obtained by mixing the chitosan modified with catechol groups, polyvinyl alcohol and water in a ratio of 0.1 g:1 g:10 mL to react to obtain solution A; mixing the MXene modified with polyphenols and Mg ions and the gelatin modified with phenylboronic acid in a mass ratio of (0.8-1.6):12.5 to react to obtain solution B; mixing solution A and B in a volume ratio of 1:1 and reacting; 2. The application according to claim 1, characterized in that The conditions of the electrical stimulation are 100 mV cm -1 .

3. The application according to claim 1, characterized in that The diabetic foot ulcer includes the diabetic foot ulcer caused by neuropathy.

4. The application according to any one of claims 1 to 3, characterized in that The conductive hydrogel plays a role in treating diabetic foot ulcers by promoting cell migration.

5. A hydrogel preparation for treating diabetic foot ulcers, characterized in that, Comprising the conductive hydrogel described in claim 1; The hydrogel preparation is combined with electrical stimulation for the combined treatment of diabetic foot ulcers.

6. The hydrogel preparation according to claim 5, characterized in that, The electrical stimulation is under the condition of 100 mV cm -1 .

7. The hydrogel preparation according to claim 5, wherein The diabetic foot ulcers include diabetic foot ulcers caused by neuropathy.

8. The hydrogel preparation according to claim 5, characterized in that, The conductive hydrogel plays a role in treating diabetic foot ulcers by promoting cell migration.

Images